AMRA Medical, a Linköping-based leader in MRI-based fat and muscle analysis, has announced an investment from HealthCap, one of Europe's most established life science venture capital firms. The announcement was made on September 14, 2026, and represents a significant step in the company's growth trajectory. It also underscores rising market confidence in the company's mission to transform how muscle and fat are measured and understood in healthcare.
A Strategic Investment in Quantitative MRI
HealthCap's backing positions AMRA to meet growing global demand for precise, scalable advanced muscle and fat imaging in clinical research and healthcare. The investment reflects the increasing importance of quantitative MRI in generating standardized biomarkers that surpass traditional measures such as weight, body mass index, and muscle function tests. AMRA's proprietary methods are built on more than 15 years of research and provide automated data necessary for modern clinical research.
Addressing a Growing Clinical Need
Quantitative MRI is becoming vital for understanding how fat distribution and muscle composition influence disease, treatment response, and patient outcomes. In metabolic and neuromuscular medicine, there is a clear shift toward more precise, biomarker-driven insights that can improve clinical research and treatment evaluation. AMRA's technology supports this shift by delivering standardized, cloud-based workflows that enable partners to access actionable data with clarity and confidence.
Executive Perspectives
Olof Dahlqvist Leinhard, Chief Executive Officer of AMRA Medical, said the next phase for the company is about translating years of scientific validation into broader clinical and research impact. He emphasized that HealthCap's extensive life sciences experience and global network will be instrumental in extending the reach of AMRA's technology. This sentiment reflects the company's ambition to move beyond research validation toward wider adoption.
Dr. Mårten Steen, Managing Partner at HealthCap, will join the AMRA board as part of the investment. He said AMRA combines differentiated technology and strong scientific validation with clear relevance to critical areas of medicine and unmet medical need. HealthCap sees significant potential for the technology as clinicians increasingly demand better data to track patient progress and treatment effects.
Planned Use of Investment
The new capital will fuel AMRA's continued research and development, product innovation, and international commercial expansion. The investment will support AMRA’s continued research and development, product innovation, and international commercial expansion.
About the Companies
AMRA Medical is a global leader in health informatics, pioneering the field of fat and muscle analysis with proprietary, MRI-based technologies. Its platform delivers highly precise and standardized biomarkers, providing an advanced understanding of metabolic and musculoskeletal health. The company's solutions are designed to meet the complex demands of modern healthcare and pharmaceutical development.
HealthCap is a European venture capital firm that has invested globally in life sciences since 1996. The firm has backed and built more than 130 companies, taken 48 public, and completed numerous trade sales. Its investment strategy targets diseases with a high unmet medical need and backs breakthrough therapies and innovative healthcare solutions with transformative potential.
The investment from HealthCap marks a pivotal moment for AMRA Medical as it seeks to expand the clinical and commercial reach of its quantitative MRI platform. With a strong scientific foundation, a clear market need, and the support of an experienced life science investor, the company is well positioned for its next phase of global growth. The partnership also highlights the broader healthcare trend toward precise, biomarker-driven insights that can improve patient care and treatment evaluation.